SCHEMBL145318

SCHEMBL145318

O=C(c1ccccc1)c1cc(Br)ccc1O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.71
CYP1A2 P05177 1/20 0.71
CYP2C9 P11712 1/20 0.71
ALOX15 P16050 1/20 0.71
CASP1 P29466 1/20 0.71
CYP2C19 P33261 1/20 0.71
GSTA1 P08263 1/20 0.71
MAPT P10636 4/20 0.69
POLB P06746 1/20 0.69
PTGES O14684 1/20 0.65
CES2 O00748 1/20 0.60
GALR3 O60755 1/20 0.60
PTGDR2 Q9Y5Y4 1/20 0.56
ALDH1A1 P00352 1/20 0.55
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
AKR1C3 P42330 1/20 0.53
USP2 O75604 1/20 0.53
GAA P10253 1/20 0.53
KEAP1 Q14145 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31172946 1.00 HPGD (0.71) HPGDCYP1A2CYP2C9ALOX15CASP1
Benzophenone SCHEMBL19519174 0.86 GSTA1 (0.62) HPGDCYP1A2CYP2C9ALOX15CASP1
SCHEMBL11350145 0.85 MEN1 (0.68) HPGDCYP1A2CYP2C9ALOX15CASP1
SCHEMBL15684683 0.84 ALOX15 (1.00) HPGDCYP1A2CYP2C9ALOX15CASP1
SCHEMBL935966 0.83 MAPT (0.71) CASP1GSTA1MAPTPOLBPTGES
SCHEMBL17193968 0.82 CYP1A2 (0.67) HPGDCYP1A2CYP2C9ALOX15CASP1
SCHEMBL30494732 0.82 CYP1A2 (0.67) HPGDCYP1A2CYP2C9ALOX15CASP1
SCHEMBL21812547 0.82 GSTA1 (0.77) HPGDCYP1A2CYP2C9ALOX15CASP1
SCHEMBL7633062 0.82 MAPT (0.69) HPGDCYP1A2CYP2C9ALOX15CASP1
SCHEMBL11641466 0.82 CYP1A2 (0.67) HPGDCYP1A2CYP2C9ALOX15CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122031284-A Sun-proof particles with multilayer core-shell structure and preparation method and application thereof 广州极钛美纳米科技有限公司 2026-05-15 CN claimed
WO-2023162998-A1 COMPOSITION INCLUDING IODO COMPOUND AND USE FOR SAME 東ソー株式会社 2023-08-31 WO claimed
CN-110761074-B Environment-friendly low-temperature water-repellent and oil-repellent composition 乳源东阳光氟有限公司 2023-08-08 CN claimed
EP-2613819-B2 LUBRICIOUS COATINGS FOR MEDICAL DEVICES BIOINTERACTIONS LTD (GB) 2020-11-25 EP claimed
EP-2613819-B1 LUBRICIOUS COATINGS FOR MEDICAL DEVICES BIOINTERACTIONS LTD (GB) 2018-01-10 EP claimed
US-8541498-B2 Lubricious coatings for medical devices BIOINTERACTIONS LTD. (GB) 2013-09-24 US claimed
EP-2613819-A1 Lubricious coatings for medical devices Biointeractions Ltd. (GB) 2013-07-17 EP claimed
WO-2012032283-A1 Lubricious coatings for medical devices BIOINTERACTIONS LTD (GB) 2012-03-15 WO claimed
US-20120059111-A1 LUBRICIOUS COATINGS FOR MEDICAL DEVICES BIOINTERACTIONS LTD. (GB) 2012-03-08 US claimed
CN-122031284-A Sun-proof particles with multilayer core-shell structure and preparation method and application thereof 广州极钛美纳米科技有限公司 2026-05-15 CN disclosed
EP-4692160-A1 ACTIVE ENERGY RAY-CURABLE COMPOSITION, ADHESIVE, AND ADHESIVE SHEET Mitsubishi Chemical Corporation (JP) 2026-02-11 EP disclosed
US-20260015527-A1 ACTIVE ENERGY RAY-CURABLE COMPOSITION, ADHESIVE, AND ADHESIVE SHEET MITSUBISHI CHEMICAL CORPORATION (JP) 2026-01-15 US disclosed
CN-118866396-A Method for evaluating damage of Maillard reaction product to body immune system 黑龙江飞鹤乳业有限公司 2024-10-29 CN disclosed
CN-118858558-A Method for evaluating damage of Maillard reaction product to body nervous system 黑龙江飞鹤乳业有限公司 2024-10-29 CN disclosed
WO-2003050098-A1 2-SUBSTITUTED THIAZOLIDINONE AND OXAZOLIDINONE DERIVATIVES FOR THE INHIBITION OF PHOSPHATASES AND THE TREATMENT OF CANCER INCYTE SAN DIEGO INCORPORATED (US) 2003-06-19 WO disclosed
US-20030008882-A1 Proteomimetic compounds and methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-01-09 US disclosed
WO-2002089738-A2 PROTEOMIMETIC COMPOUNDS AND METHODS YALE UNIVERSITY (US) 2002-11-14 WO disclosed
US-4570006-A ANTITHROMBIN; ENZYME AND HORMONE INHIBITORS TORII & CO. LTD. (JP) 1986-02-11 US disclosed
US-4514416-A Amidine compound, process for producing same and anti-complement agent comprising same TORII & CO. LTD. (JP) 1985-04-30 US disclosed
US-4125538-A ANALGESIC, ANTITUSSIVE BRISTOL-MYERS COMPANY (US) 1978-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008882-A1 Proteomimetic compounds and methods PACSIN2, HSP90B1, PHLPP2 HPGD 3501/4885CYP1A2 4661/4885CYP2C9 4786/4885
US-20260015527-A1 ACTIVE ENERGY RAY-CURABLE COMPOSITION, ADHESIVE, AND ADHESIVE SHEET CDH1, COL1A1, EPCAM HPGD 3612/4885CYP1A2 4304/4885CYP2C9 4220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.